As Halol Remediation Prolongs, Sun Evaluates Plan B
This article was originally published in PharmAsia News
Executive Summary
A decline in Sun Pharma’s U.S. sales during the fourth quarter has sent nervous signals to investors. Most blame the drop on the FDA’s review of the firm’s Halol site, but Sun may be drawing up an alternative supply plan.